Fe3O4 and bimetal–organic framework Zn/Mg composite peroxide-like catalyze luminol chemiluminescence for specific measurement of atropine in Datura plant

Atropine (AT) is an anticholinergic drug. AT is abundantly in Datura plant seeds. Fe₃O₄@Zn/Mg MOF (Fe₃O₄@MOF) composite was synthesized. The compound had a high peroxidase-like activity in a chemiluminescence (CL) reaction. Addition of AT quenched CL. The linear range and limit of detection were 5–600 μg L⁻¹ and 2 × 10⁻² μg L⁻¹. This method is fast, reversible, and selective, without biodegradability effects, high accuracy, and precision for measuring AT in the Datura plant.     

4th European Antibody Congress 2008: December 1–3, 2008, Geneva,Switzerland

The Fourth European Antibody meeting, organized by Terrapin Ltd., was held in Geneva, a center of the European biopharmaceutical industry. Merck-Serono, NovImmune, Pierre Fabre and Therapeomic are located nearby, as are R&D centers of Boehringer-Ingelheim, Novartis, Roche and Sanofi-Aventis. Over 40 speakers and more than 200 delegates attended the event. Companies represented included Abbott, Ablynx, Adnexus/ BMS, Astra-Zeneca/ CAT/ Medimmune, BiogenIdec, BioRad, Centocor (Johnson & Johnson), Crucell/DSM, Domantis, Dyax, Genmab, Genzyme, Glycart/ Roche, Haptogen, Immunogen, Kyowa-Kirin, LFB, Medarex, Merck-Serono, Micromet, Novartis, Pierre Fabre Laboratories, Roche, Sanofi-Aventis, Seattle-Genetics, Transgene, UCB Celltech and Wyeth. Other attendees included those based in academe or government (University of Amsterdam, University of Zurich, Univeristy Hospital-Lyon, Ecole Polytechnique Federale de Lausanne, INSERM, Tufts University, US National Institutes of Health), consultants, and patent attorneys (Edwards, Angell, Palmer & Dodge). The meeting was very interactive and included exchanges during the many scheduled networking times (exhibitions, speed-networking, lunches and evening receptions). The first day of the three day conference was dedicated to advances in understanding antibody structure-function relationships. Challenges and opportunities in antibody development were the focus of the second day and the third day featured discussion of innovative antibodies and antibody alternatives.

• MAbs. 2009 Mar-Apr; 1(2): 93–103.
»
• December 1, 2008 Day 1, Therapeutic antibodies: Advances in dissecting structure-function relationships

MAbs. 2009 Mar-Apr; 1(2): 93–103.

December 1, 2008 Day 1, Therapeutic antibodies: Advances in dissecting structure-function relationships

Alain BeckAuthor information Article notes Copyright and License information DisclaimerDepartment of Physico-Chemistry; Center of Immunology Pierre Fabre; Saint-Julien-en-Genevois, FranceCorresponding author.Correspondence to: Alain Beck; Centre d''Immunologie Pierre Fabre; 5 avenue Napoleon III; Saint-Julien-en-Genevois 74160 France; Email: moc.erbaferreip@kceb.nialaReceived 2009 Jan 20; Accepted 2009 Jan 20.Copyright © 2009 Landes BioscienceThe chairman, Alain Beck (Centre d''Immunologie Pierre Fabre), opened the meeting with the following remarks: Monoclonal antibodies (mAbs) and related-products (immunoconjugates, radioimmuno-conjugates, Fab fragments and Fc-fusion proteins) are the fastest growing class of pharmaceuticals, with nearly 30 products currently approved for a wide range of indications.^3,14 In just the last three years, six new antibodies and derivatives have reached the market. These included molecules that are novel formats, as well as first in class drugs in new therapeutic indications. In 2006, panitumumab (Vectibix) was the first fully human IgG2 mAb generated by immunization of humanized transgenic mice and the second anti-EGFR mAb to gain approval. Also in 2006, ranibizumab (Lucentis), the first E. coli-produced Fab fragment and the first affinity matured antibody, was approved as a treatment age-related macular degeneration. Later, tocilizumab (Actemra) a conventional IgG1, but directed against a new target (IL-6R), was registered in Japan; BLAs are pending both in the US and in Europe. In 2007, eculizumab (Soliris) was approved for paroxysmal nocturnal hemoglobinuria. Eculizumab was constituted by an original IgG2/4 hybrid format, and is unable to bind Fc receptors or activate the complement cascade. In 2008, rinolacept (Arcalyst), an IL-1R-Fc fusion protein also called IL-1 trap, was registered for cryopyrin-associated periodic syndromes. Also in 2008, certolizumab pegol (Cimzia) became the first PEGylated Fab fragment to gain approval. The product, indicated for Crohn disease, is produced in E. coli and conjugated to large PEG residues (40 kDa). Interestingly, from a structure-function standpoint, certolizumab was crystallized and the 3D model of this original PEG-Fab was recently reported.⁴ In addition to these six new antibody or antibody-related product approvals, the first two biosimilar antibodies, Reditux (a copy of rituximab developed by Dr Reddy) and Clotinab (a biogeneric of abciximab developed by ISU ABXIS), were recently launched in India and in South Korea, respectively. Active discussions are ongoing regarding whether such generic biopharmaceuticals may also be approved in Europe, following approval of other glycoproteins such as erythropoietin.¹⁶     

Optical analysis of RE3+ (RE = Nd or Er):B2O3–P2O5–CaF2–ZnO–(Li2O/Na2O/K2O) glasses

Calcium boro fluoro zinc phosphate glasses modified using alkali oxide and doped with Nd³⁺ and Er³⁺ ions with the chemical composition of 69.5 (B₂O₃) + 10 (P₂O₅) + 10 (CaF₂) + 5 (ZnO) + 5 (Na₂O/Li₂O/K₂O) + 0.5 (Er₂O₃/Nd₂O₃) were prepared using a conventional melt quenching technique. The results of X-ray diffraction patterns indicated the amorphous nature of all the prepared glasses. The visible–near-infrared red (NIR) absorption spectra of these glasses were analyzed systematically. The NIR emission spectra of Er³⁺ and Nd³⁺:calcium boro fluoro zinc phosphate glasses showed prominent emission bands at 1536 nm (⁴I_13/2→⁴I_15/2) and 1069 nm (⁴F_3/2→⁴I_11/2) respectively with λ_exci = 514.5 nm (Ar⁺ laser) as the excitation source.     

Fe3O4/ 生物可降解复合材料研究

磁性氧化铁纳米粒子因具有尺寸小、低毒性和超顺磁性等特点,已经引起了生物化工、医药工业领域的广泛关注。生物可降解高分子材料是生物医用高分子研究中最活跃的领域之一,已广泛用于外科手术缝合线,植入体材料及药物释放载体等。将Fe3O4和生物可降解高分子材料进行复合,可以扩大两者的应用范围,达到理想的治疗效果,并有望开创临床治疗的新时代。本文介绍了磁性四氧化三铁粒子的化学制备方法,包括共沉淀法、溶胶-凝胶法、微乳液法,并对各种方法的优缺点进行了比较;重点阐述了磁性壳聚糖,磁性聚乳酸,磁性PEG,磁性PCL复合材料的制备,及它们在酶的固定化、磁靶向药物及基因载体等医学领域的应用,显示了Fe3O4/生物可降解复合材料在医学领域的广阔应用前景;最后对复合材料走向临床应用所面临的问题及发展前景进行了讨论。     

Measles Case Fatality Rate in Bihar,India, 2011–12

Background

Updated estimates of measles case fatality rates (CFR) are critical for monitoring progress towards measles elimination goals. India accounted for 36% of total measles deaths occurred globally in 2011. We conducted a retrospective cohort study to estimate measles CFR and identify the risk factors for measles death in Bihar–one of the north Indian states historically known for its low vaccination coverage.

Methods

We systematically selected 16 of the 31 laboratory-confirmed measles outbreaks occurring in Bihar during 1 October 2011 to 30 April 2012. All households of the villages/urban localities affected by these outbreaks were visited to identify measles cases and deaths. We calculated CFR and used multivariate analysis to identify risk factors for measles death.

Results

The survey found 3670 measles cases and 28 deaths (CFR: 0.78, 95% confidence interval: 0.47–1.30). CFR was higher among under-five children (1.22%) and children belonging to scheduled castes/tribes (SC/ST, 1.72%). On multivariate analysis, independent risk factors associated with measles death were age <5 years, SC/ST status and non-administration of vitamin A during illness. Outbreaks with longer interval between the occurrence of first case and notification of the outbreak also had a higher rate of deaths.

Conclusions

Measles CFR in Bihar was low. To further reduce case fatality, health authorities need to ensure that SC/ST are targeted by the immunization programme and that outbreak investigations target for vitamin A treatment of cases in high risk groups such as SC/ST and young children and ensure regular visits by health-workers in affected villages to administer vitamin A to new cases.     

How relevant are S=O and P=O Double Bonds for the Description of the Acid Molecules H2SO3, H2SO4, and H3PO4, respectively?

The acid molecules H₂SO₃, H₂SO₄, and H₃PO₄ are usually drawn using "Lewis structures" which exhibit the octet extension by 3d-orbitals on sulfur and phosphorus, respectively. Thus, S=O and P=O double bonds are assumed to be formed. The natural d-orbital occupancies on S and P, however, were calculated to be as low as 0.1 e, and therefore, an octet extension can hardly be expected. After the natural bond orbitals (NBO) search procedure was forced to attempt to form different Lewis structures of bonds and lone pairs, we defined the optimal Lewis structure, if a dominant structure exists at all, by the maximum electronic charge in Lewis orbitals. Indeed, sulfur obeys the octet rule in the optimal zwitterionic Lewis structures and does not form S=O double bonds. No dominant resonance structure could be found for H₃PO₄ where polarized PO ?-bond and zwitterionic PO bond structures exhibit similar weights.     

Thermoluminescence dosimetric attributes of Yb3+-doped BaO–ZnO–LiF–B2O3 glass material after Er3+ co-doping

Motivated by our previous study on Sm³⁺ ions as thermoluminescence (TL) sensitizers to the BaO–ZnO–LiF–B₂O₃–Yb₂O₃ glass system, in the current study we examined the effect of Er³⁺ ion co-doping on the TL characteristics of this glass system. The 4f–4f electronic transitions of the Er³⁺ and Yb³⁺ ions were confirmed via the optical absorption spectrum. Notably, the use of Yb³⁺–Er³⁺ ions failed to improve the TL intensity, sensitivity, and trap density. However, they enabled the glass system to function as an activator–quencher system. The linearity range and effective atomic number remained unaffected after co-doping. In addition, the problem of anomalous fading caused a remnant signal of just 58% after a week of storage of the Yb³⁺ monodoped glass. This was resolved by the optimum co-doping of Er³⁺ ions to achieve an 89% signal. The co-doping of Er³⁺ ions to the BaO–ZnO–LiF–B₂O₃–Yb₂O₃ glass system regulated its thermal stability and therefore supplemented its potential for radiation monitoring in food processing and retrospective dosimetry.     

Cancer Immunotherapy 2005: Mainz, Germany, 12–13 May 2005

Cancer Immunotherapy 2005 was the third international meeting organized by the Association for Immunotherapy of Cancer (AIC). About 200 participants were attracted by the excellent scientific program that consisted of overview lectures from 25 international speakers in the plenary auditorium and four guided poster sessions during both days of the meeting. The first day of the symposium mainly focused on experience with, and new perspectives in, antibody therapy. On the second day of the meeting, organized as a joint conference together with the Combined Research Grant “Mechanisms of Tumor Defense and Therapeutic Intervention” funded by the German Research Council, the participants had the chance to gain deeper insights into the principles of antigen processing and the regulation of immune responses. Further topics that were discussed mainly in the poster sessions and in the special lecture given by M. Nishimura (Chicago, USA), were “cellular therapies” and “vaccination against cancer”. The lectures selected for this report aim to provide an overview of the complete scientific program and give an impression of the lively atmosphere that could be felt from the first until the last session of CIMT 2005. C.M. Britten and C. Gouttefangeas contributed equally to this report.     

Uric acid salts of magnesium: crystal and molecular structures and thermal analysis of two phases of Mg(C5H3N4O3)2 · 8H2O

Two structurally different phases of a uric acid salt of magnesium, Mg(hydrogenurate)₂ · 8H₂O, have been prepared by crystallization from solution at pH = 7.5–8.0 and were investigated by x-ray crystallography, thermal analysis, and ir spectroscopy. Both phases are monoclinic, space group P2₁/c with a = 9.573(2), b = 14.627(3), c = 7.170(1) Å, β = 101.91(1)° (phase I) and a = 10.397(2), b = 14.306(3), c = 6.732(1) Å, β = 104.64(2)° (phase II). The crystal structures of both phases (R = 0.053 and 0.051, respectively) contain isolated octahedral [Mg(H₂O)₆]²⁺ cations, hydrogenurate monoanions, and two molecules of water of crystallization per formula unit. The structural formula representing these facts is [Mg(H₂O)₆] (hydrogenura-te)₂·2H₂O. The tautomeric form of the hydrogenurate molecule corresponds to the tri-keto form of uric acid deprotonated at N(3). Differences in bond length between uric acid and the hydrogenurate molecule may be described in terms of three additional resonance structures distributing the formal negative charge at N(3) within the pyrimidine (but not the imidazole) ring. Deprotonation at N(3) significantly decreases the internal C-N-C angle at N(3). Alternating pairs of medium-strong intermolecular N-HO hydrogen bonds lead to infinite chains of hydrogenurate molecules extending along the b axis of the unit cells in both phases. The main difference between the two phases lies in their stacking pattern of the hydrogenurate molecules. Infrared data confirm the hydrogen bonding characteristics resulting from the crystal structure analysis. Thermogravimetric measurements and differential scanning calorimetry data show that the dehydration of both phases occurs in two distinct steps with Mg(hydrogenurate)₂.6H₂O as an intermediate phase. The first dehydration step (−2H₂O) is a topotactic reaction with three-dimensional preservation of the main structure elements of the octahydrate in the structure of the hexahydrate.     

Fe–O versus O–O bond cleavage in reactive iron peroxide intermediates of superoxide reductase

It is generally accepted that the catalytic cycles of superoxide reductases (SORs) and cytochromes P450 involve a ferric hydroperoxo intermediate at a mononuclear iron center with a coordination sphere consisting of four equatorial nitrogen ligands and one axial cysteine thiolate trans to the hydroperoxide. However, although SORs and P450s have similar intermediates, SORs selectively cleave the Fe–O bond and liberate peroxide, whereas P450s cleave the O–O bond to yield a high-valent iron center. This difference has attracted the interest of researchers, and is further explored here. Meta hybrid DFT (M06-2X) results for the reactivity of the putative peroxo/hydroperoxo reaction intermediates in the catalytic cycle of SORs were found to indicate a high-spin preference in all cases. An exploration of the energy profiles for Fe–O and O–O bond cleavage in all spin states in both ferric and ferrous models revealed that Fe–O bond cleavage always occurs more easily than O–O bond cleavage. While O–O bond cleavage appears to be thermodynamically and kinetically unfeasible in ferric hydrogen peroxide complexes, it could occur as a minor (significantly disfavored) side reaction in the interaction of ferrous SOR with hydrogen peroxide.